Clinical Trials · NCT03060980
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Intarcia Therapeutics
- Enrollment
- 245
- Start date
- Mar 2017
- Locations
- 101 sites, United States, Canada
- Primary endpoint
- Reduction in glycosylated hemoglobin A1c